Breast cancer metastasis

Pharmatest breast cancer metastasis models are suitable for testing the efficacy of drug compounds against several dissemination processes and growth in specific micro environments. The metastasis models are demanding for the drug candidate, but exhibit excellent clinical predictivity.

Description

Pharmatest offers two types of translational breast cancer metastasis models:

• The experimental intracardiac xenograft model is a clinically predictive model of cancer-induced bone disease that develops primarily bone metastases with at least 70 per cent tumor incidence.
• The spontaneous syngeneic orthotopic model in turn develops metastases primarily to the lungs with at least 95 per cent tumor incidence.

In the bone metastasis model radiography and dynamic fluorescence imaging reveal the progression of the disease. The data is analyzed for tumor burden with in-bone metastasis studies also focusing on bone lesion numbers and area. Histology samples can be analyzed for tumor area, trabecular bone area and osteoclast number to reveal detailed information about the test compound’s effects on bone metastases.

Where the focus is on cancer bone metastases, researchers should also consider Pharmatest’s in vitro bone cell assays, which are useful for testing novel cancer drug compounds, especially those targeting the vicious cycle of cancer-induced bone disease.

Resources

Click on breast cancer metastasis models for other information.
Click on Pharmatest to contact the company directly.

Supplier Information
Supplier: Pharmatest Services Ltd
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com